Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | BGB-43395 |
| Trade Name | |
| Synonyms | BGB43395|BGB 43395 |
| Drug Descriptions |
BGB-43395 selectively inhibits CDK4, potentially resulting in cell cycle arrest and decreased tumor cell proliferation (NCI Drug Dictionary). |
| DrugClasses | CDK4 Inhibitor 18 |
| CAS Registry Number | NA |
| NCIT ID | C203660 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BG-68501 + BGB-43395 + Fulvestrant | BG-68501 BGB-43395 Fulvestrant | 0 | 1 |
| BG-75098 + BGB-43395 + Fulvestrant | BG-75098 BGB-43395 Fulvestrant | 0 | 1 |
| BGB-21447 + BGB-43395 + Fulvestrant | BGB-21447 BGB-43395 Fulvestrant | 0 | 1 |
| BGB-43395 | BGB-43395 | 0 | 1 |
| BGB-43395 + Elacestrant | BGB-43395 Elacestrant | 0 | 1 |
| BGB-43395 + Fulvestrant | BGB-43395 Fulvestrant | 0 | 1 |
| BGB-43395 + Letrozole | BGB-43395 Letrozole | 0 | 1 |